Skip to content
Clinical Trials – home
VerifiedinfoResponsive

Spitalul Clinic Judetean De Urgenta Cluj

Romania Strada Clinicilor 3-5, 400006 Cluj Napoca, Romania

  • 30 trials recruiting
  • Systemic lupus erythematosus · Colitis ulcerative · Sjogren's syndrome
  • Adults and children

About Specializations

Spitalul Clinic Judetean De Urgenta Cluj in Cluj Napoca, Romania specialises in clinical trials of conditions such as Systemic lupus erythematosus, Colitis ulcerative, Sjogren's syndrome, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Immunology and Rheumatology Research

At Spitalul Clinic Judetean De Urgenta Cluj, clinical trials in immune system processes and rheumatology focus on Systemic Lupus Erythematosus, a complex autoimmune disease that can cause widespread inflammation and organ involvement. The research is designed to assess whether new treatments can better control symptoms and improve long-term disease management for adults with active disease.

  • Evaluating a new therapy for Systemic Lupus Erythematosus to improve signs and symptoms
  • Assessing safety and overall treatment effectiveness in adults with moderate to severe disease
  • Following patients over time to better understand long-term control of autoimmune activity

These studies reflect a strong interest in advancing care for inflammatory and autoimmune conditions, with an emphasis on safer and more effective options for patients living with SLE.

Metabolic Disease and Diabetes Studies

The site also supports research in nutritional and metabolic diseases, with a focus on type 2 diabetes. These trials aim to improve blood sugar control and support better treatment outcomes for people whose diabetes remains difficult to manage on standard therapy.

  • Testing a new treatment approach for type 2 diabetes in people with inadequate glycaemic control
  • Comparing blood sugar and weight outcomes against established diabetes therapies
  • Exploring ways to strengthen routine diabetes care for patients using background treatment such as metformin

Research in this area combines metabolic health and treatment effectiveness, helping clarify whether newer options can offer meaningful benefits for people with diabetes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Strada Clinicilor 3-5400006 Cluj NapocaRomania
Recruiting now
30 trials
Conditions studied
52
Partner status
Verified

More sites in Cluj NapocaRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

79 clinical trials

Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).